Skip to main content

Antengene Completes $340 Million Hong Kong IPO for Oncology Drugs

Shanghai Antengene, a three-year old oncology company, completed a $340 million IPO in Hong Kong . The company, which was originally backed by Celgene, said the offering was significantly oversubscribed. Antengene has built a portfolio of 12 first-in-class, only-in-class and best-in-class cancer therapies, six of which have begun clinical trials. It combines in-licensings with internal research. The company says it uses a synergistic approach to "unlock the full therapeutic potential" of its candidates. More details.... Stock Symbol: (HK: 6996) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.